daily oral glp-1 receptor agonist orforglipron for adults with obesity 272 participants randomized. Baseline Mean body weight : 108.7 kg Mean weight loss at week 26: −8.6% to −12.6% dose cohorts −2.0% in the placebo group. ➡️Daily orforglipron, a nonpeptide WIKIMOLE—Orforglipron
Description
This is not a suggestion
Current Pipeline The current pipeline for GLP-1 RAs is robust with 1,465 clinical trials in various stages
But the expert consensus is now that semaglutide and other GLP-1 drugs do not increase the risk of pancreatitis, says Drucker
Track your food intake using an app or journal to maintain awareness
Prescribing information (Amneal Pharmaceuticals, 2025)
Alongside nausea, many people experience vomiting, diarrhea, constipation, and abdominal discomfort
